- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06310031
[Испытание устройства, которое не одобрено или не одобрено FDA США] (INNOVATE)
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
The INNOVATE Trial is a prospective, non-blinded, randomized, controlled, multi-center, non-inferiority study to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3™ (HM3) LVAS (Abbott) when used for the treatment of advanced, refractory left ventricular heart failure. It is the first clinical study to compare two left ventricular assist devices (LVAD) that belong to the same category of fully magnetically levitated LVAD.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35233
- University of Alabama at Birmingham Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Соединенные Штаты, 72205
- Baptist Health Medical Center-Little Rock
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90048
- Cedars-Sinai Medical Center
-
-
Florida
-
Gainsville, Florida, Соединенные Штаты, 32608
- UF Health Shands Hospital
-
Orlando, Florida, Соединенные Штаты, 32803
- Advent Health
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Emory University
-
Atlanta, Georgia, Соединенные Штаты, 30309
- Piedmont Healthcare
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern University
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago
-
Chicago, Illinois, Соединенные Штаты, 60453
- Advocate Christ Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46260
- Ascension St. Vincent Hospital - Indianapolis
-
-
Kansas
-
Kansas City, Kansas, Соединенные Штаты, 66160
- The University Of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Соединенные Штаты, 40536
- University of Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40202
- University of Louisville
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21201
- University of Maryland Medical Center
-
Baltimore, Maryland, Соединенные Штаты, 21287
- The Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Соединенные Штаты, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- University of Michigan
-
Detriot, Michigan, Соединенные Штаты, 48202
- Henry Ford Health
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Corewell Health Grand Rapids Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55455
- University of Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55407
- Abbott Northwestern Hospital
-
-
Missouri
-
St Louis, Missouri, Соединенные Штаты, 63110
- WashU Medicine
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68198
- University of Nebraska Medical Center
-
-
New Jersey
-
Newark, New Jersey, Соединенные Штаты, 07112
- Newark Beth Israel Medical Center
-
-
New York
-
New York, New York, Соединенные Штаты, 10065
- Weill Cornell Medicine
-
New York, New York, Соединенные Штаты, 10016
- NYU Langone Health
-
New York, New York, Соединенные Штаты, 10029
- Mount Sinai
-
New York, New York, Соединенные Штаты, 10032
- Columbia University Irving Medical Center/ New York Presbyterian Hospital
-
The Bronx, New York, Соединенные Штаты, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, Соединенные Штаты, 27710
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45219
- The Christ Hospital - Cincinnati
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Thomas Jefferson University Hospital
-
-
South Carolina
-
Charleston, South Carolina, Соединенные Штаты, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Соединенные Штаты, 38120
- Baptist - Memphis (Stern)
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75246
- Baylor University Medical Center, part of Baylor Scott & White Health
-
Dallas, Texas, Соединенные Штаты, 75390
- UT southwestern Medical Center
-
Houston, Texas, Соединенные Штаты, 77030
- Houston Methodist Hospital
-
Houston, Texas, Соединенные Штаты, 77030
- Memorial Hermann-Texas Medical Center
-
Houston, Texas, Соединенные Штаты, 77030
- Texas Heart Institute at Baylor St. Luke's Medical Center
-
Plano, Texas, Соединенные Штаты, 75093
- Baylor Scott & White Medical Center - Plano
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84132
- University of Utah
-
-
Virginia
-
Falls Church, Virginia, Соединенные Штаты, 22042
- Inova Fairfax Medical Campus
-
-
Wisconsin
-
Milwaukee, Wisconsin, Соединенные Штаты, 53215
- Aurora St. Luke's Medical Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Patient is ≥ 18 years of age.
-
Patient has received institutional approval for LVAD implantation.
-
Patient has a body surface area (BSA) ≥ 1.2 m2.
-
Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.
-
Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF < 30% on inotropes or temporary MCS.
-
Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters/min/m2, while not on inotropes, and also meets one of the following criteria:
- Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or
- Has advanced heart failure for at least 14 days and is dependent on an intra-aortic balloon pump (IABP) or temporary mechanical circulatory support device (MCSD) for at least seven days.
-
Patient has provided voluntary and informed consent.
-
Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.
Exclusion Criteria:
-
Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and/or pericardial disease.
-
Patient had a myocardial infarction within seven days of study enrollment.
-
Patient had cardiothoracic surgery within 30 days of implant with the exception of a procedure to implant temporary MCS: Impella 5.5, Impella CP or TandemHeart.
-
Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.
-
Patient has contraindications to warfarin anticoagulation.
-
Patient has known hypo- or hypercoagulable state [e.g., disseminated intravascular coagulation (DIC)], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.
-
Patient is on durable MCS (e.g., LVAD or RVAD).
-
Planned need for durable or temporary RVAD support concomitant with LVAD implant.
-
Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an intra-aortic balloon pump, Impella 5.5, Impella CP, or TandemHeart.
-
Patient is on any form of pre-implant temporary MCS and has a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or plasma free hemoglobin > 40 g/dL.
-
Patient has a history of organ transplantation.
-
Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.
-
Patient has a platelet count < 50 k/μl.
-
Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter.
-
Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.
-
Patient has an uncontrolled systemic infection.
-
Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin >1000 ug/L.
-
Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:
- Total bilirubin > 3.0 mg/dL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.
- International normalized ratio (INR) ≥ 2.0 or PTT > 2.5 times control that is not related to anticoagulation therapy.
- Glomerular filtration rate (GFR) < 30 mL/ min/1.73 m2 or need for renal replacement therapy.
- Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.
- Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1/FVC < 0.7 and FEV1 < 40% predicted.
- Mechanical ventilation for more than three days present at the time of study enrollment.
- Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.
- History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.
- Symptomatic cerebrovascular disease and/or uncorrected carotid stenosis > 80%.
- Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.
- Pre-albumin < 15 mg/dL and/or albumin < 2.5 g/dL.
-
Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.
-
Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and/or insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.
-
Patient is participating in an interventional clinical trial that may impact or confound the results of the INNOVATE Trial.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: BrioVAD System
BrioVAD® Left Ventricular Assist System (BrioVAD® System) by BrioHealth Solutions, Inc. |
Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure. |
|
Активный компаратор: HeartMate 3
HeartMate 3 System by Abbott |
Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Short-Term Indication Primary Endpoint
Временное ограничение: 6 months
|
Composite of survival to transplant, recovery or 6 months of LVAD support free of debilitating stroke [modified Rankin Scale (mRS) > 3], or reoperation to replace the pump |
6 months
|
|
Long-Term Indication Primary Endpoint
Временное ограничение: 24 months
|
Composite of survival to transplant, recovery or 24 months of LVAD support free of debilitating stroke (mRS > 3), or reoperation to replace the pump. |
24 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Powered Secondary Endpoint
Временное ограничение: 24 months
|
Total number of nights in hospital, skilled nursing facility, or inpatient rehabilitation, inclusive of index hospitalization, through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. |
24 months
|
|
Short-Term Indication Secondary Endpoint
Временное ограничение: 6 months
|
Evaluation of the short-term safety using INTERMACS adverse event (AE) terms and definitions through 6 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 6 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. Serious adverse events (SAEs) will be analyzed in a similar manner. |
6 months
|
|
Long-Term Indication Secondary Endpoint
Временное ограничение: 24 months
|
Evaluation of the long-term safety using INTERMACS AE terms and definitions through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 24 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. SAEs will be analyzed in a similar manner |
24 months
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CL-00545
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Protocol and data is company confidential.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .